Skip to main
  1. Stocks
  2. Haemonetics
  3. Forecast
HAE

Haemonetics (HAE) Stock Forecast & Price Target

Haemonetics (HAE) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 50%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Haemonetics is supported by strong fundamental momentum, as F2Q27 revenue rose 9% reported and 10% organic to $357.8 million while adjusted EPS of $1.35 beat expectations, with all segments outperforming. Its Plasma franchise is the key growth engine, aided by high-single-digit global collection growth, Persona PLUS adoption, and the return of CSL as a customer across ~300 U.S. centers by calendar year 2027, which should add durable recurring revenue. The company also benefits from improving profitability and cash generation, including a Plasma operating margin of roughly 34% to 35%, quarterly free cash flow of $103.8 million, and FCF conversion above 80% guided for FY27.

Bears say

Haemonetics is exposed to meaningful regulatory and operational risk because it operates in a highly scrutinized FDA environment, where adverse observations, warning letters, or product recalls could quickly pressure sales and investor confidence. The company also sole-sources some raw materials and components, creating vulnerability to supply shortages that could disrupt production and cause lost sales, while its reliance on cost-cutting and efficiency programs adds execution risk if the expected benefits fail to materialize. On top of that, the MedTech sector’s heavy intellectual property burden raises the chance of infringement disputes or lengthy, expensive litigation, further threatening margins and the company’s overall financial profile.

Haemonetics (HAE) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 50% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Haemonetics and is not a guaranteed prediction by Public.com or investment advice.

Haemonetics (HAE) Analyst Forecast & Price Prediction

Get the latest Haemonetics (HAE) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Haemonetics (HAE)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Haemonetics (HAE) Forecast

Analysts have given Haemonetics (HAE) a Buy based on their latest research and market trends.

According to 10 analysts, Haemonetics (HAE) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $128, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $128, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Haemonetics (HAE)


Haemonetics (HAE) Analyst Forecast & Price Prediction

Get the latest Haemonetics (HAE) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Haemonetics (HAE)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover HAE stock data and trends